These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 10172482)

  • 21. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fresh Approaches to Addressing High Drug Costs.
    Armstrong J; Becker C
    NCSL Legisbrief; 2019 Apr; 27(15):1-2. PubMed ID: 30990598
    [No Abstract]   [Full Text] [Related]  

  • 23. Restrictions on the reimbursement policy with regard to retail marketing of medicinal products in Poland.
    Zimmermann A
    Acta Pol Pharm; 2013; 70(2):339-43. PubMed ID: 23614291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea.
    Heo JH; Rascati KL; Lee EK
    Value Health Reg Issues; 2017 May; 12():7-19. PubMed ID: 28648319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Policy in Hungary.
    Inotai A; Csanádi M; Harsányi A; Németh B
    Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pricing and reimbursement of drugs in Sweden.
    Lundkvist J
    Eur J Health Econ; 2002; 3(1):66-70. PubMed ID: 15609120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
    [No Abstract]   [Full Text] [Related]  

  • 29. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Medical problems associated with the national reference pricing system in Hungary].
    Kerpel-Fronius S
    Orv Hetil; 2004 Apr; 145(17):913-8. PubMed ID: 15170969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Drug Reimbursement and Pricing Policy in Taiwan.
    Chen GT; Chang SC; Chang CJ
    Value Health Reg Issues; 2018 May; 15():127-132. PubMed ID: 29704659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-26. PubMed ID: 19301435
    [No Abstract]   [Full Text] [Related]  

  • 33. The effects of new pricing and copayment schemes for pharmaceuticals in South Korea.
    Lee IH; Bloor K; Hewitt C; Maynard A
    Health Policy; 2012 Jan; 104(1):40-9. PubMed ID: 22000599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pricing and reimbursement of pharmaceuticals in Belgium.
    Annemans L; Crott R; De Clercq H; Huybrechts M; Peys F; Robays H; Steens I; Vanschoubroek K; Winderickx P
    Pharmacoeconomics; 1997 Mar; 11(3):203-9. PubMed ID: 10165309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand.
    Danzon PM; Ketcham JD
    Front Health Policy Res; 2004; 7():1-54. PubMed ID: 15612334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
    Rosenberg ME; Rosenberg SP
    JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical expenditure in Spain: cost and control.
    Lopez Bastida J; Mossialos E
    Int J Health Serv; 2000; 30(3):597-616. PubMed ID: 11109184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.